Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors - Join Clinical Trial NCTNCT04985604
How to Join This Clinical Trial - NCTNCT04985604
Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation. Current status: TERMINATED.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1, PHASE2 - Safety and effectiveness study
- Enrollment Status
- TERMINATED
- Study Identifier
- NCTNCT04985604 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 20 locations. Find a study site near you:
Clinical Research Site
Los Angeles, California 90025 - United States
Status: Contact for availability
Clinical Research Site
Newport Beach, California 92663 - United States
Status: Contact for availability
Clinical Research Site
Aurora, Colorado 80045 - United States
Status: Contact for availability
Clinical Research Site
Jacksonville, Florida 32256 - United States
Status: Contact for availability
Clinical Research Site
Indianapolis, Indiana 46250 - United States
Status: Contact for availability
Clinical Research Site
Portland, Oregon 97239 - United States
Status: Contact for availability
Clinical Research Site
Pittsburgh, Pennsylvania 15213 - United States
Status: Contact for availability
Clinical Research Site
Nashville, Tennessee 37232 - United States
Status: Contact for availability
Clinical Research Site
Clayton, Victoria - Australia
Status: Contact for availability
Clinical Research Site
Edegem, - Belgium
Status: Contact for availability
And 10 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE1, PHASE2 clinical trial for Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai as Your Clinical Trial Matching Service
Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:
- Find clinical trials that match your condition
- Get matched to the right study location near you
- Connect directly with study coordinators
- Understand if you qualify with simplified eligibility screening
- Navigate the enrollment process with personalized support
- Access new treatments through clinical research participation